Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
暂无分享,去创建一个
P. Lønning | S. Lundgren | S. Knappskog | R. Chrisanthar | E. Løkkevik | G. Anker | B. Østenstad | T. Risberg | I. Mjaaland | H. Miletic | B. Leirvaag